Inrig Jula

CMO Inrig Jula executes mixed buy-sell activity, acquiring shares while near 52-week highs amid company operating losses.

CMO Inrig Jula conducted a complex set of transactions on consecutive business days, purchasing a total of approximately 24,250 shares while simultaneously selling 22,485 shares, resulting in a net addition of roughly 1,765 shares to his position. The transactions occurred when the stock was trading near its 52-week high after a substantial rally, which is atypical for insider conviction — most insider buying occurs during weakness, not strength. Jula's last transaction in Travere shares, a sale in late December, is too recent to evaluate its outcome, preventing assessment of whether this follow-up activity represents profitable repositioning or a change in outlook. The company itself is operating at a loss with negative earnings, which adds risk to the underlying investment thesis. The simultaneous buying and selling pattern, combined with the stock's elevated price level, suggests tactical portfolio rebalancing rather than a clear bullish conviction signal.

CMO Inrig sells 15,000 TVTX shares at $42.00; holds 88,787 shares post-transaction amid 62.7% 90-day rally.

Jula Inrig, Chief Medical Officer, sold 15,000 shares (15.0K shares) of Travere Therapeutics at $42.00 on 2025-12-24, retaining 88.8K shares. This sale occurred on a day when the stock was trading at $38.88 current price, within a 52-week range of $13.49–$40.28, and represents a 14.5% reduction in her pre-transaction holdings of 103.8K shares. The broader context shows strong recent price momentum: the stock has risen 62.7% over the past 90 days and 9.8% over the past 30 days. The company posted $164.9M in latest quarterly revenue with $25.7M net income in that quarter, though it reported negative full-year net income over its most recent complete fiscal year despite 60.6% annual revenue growth. The sale by a medical officer of the company occurred above the stock's current price and at a point of significant recent appreciation, warranting monitoring of whether this represents opportunistic execution or an early signal of internal sentiment about valuation or strategy.